To confirm that IL‐22 has no influence on the cell proliferation during hyperplasia and adenoma/MIN stages of breast tumor progression, i.v. injections of recIL‐22 (40 μg·week−1) were given to IL‐22+/+/PyMT mice at 4 and 5 weeks of age. This evidence concerns the gene IL22 and breast neoplasm.